These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
638 related articles for article (PubMed ID: 8913937)
1. Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program. Eggermont AM; Manusama ER; ten Hagen TL J Inflamm; 1995-1996; 47(1-2):104-13. PubMed ID: 8913937 [TBL] [Abstract][Full Text] [Related]
2. TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Eggermont AM Anticancer Res; 1998; 18(5D):3899-905. PubMed ID: 9854502 [TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program. Manusama ER; Nooijen PT; Ten Hagen TL; Van Der Veen AH; De Vries MW; De Wilt JH; Van Ijken MG; Marquet RL; Eggermont AM Semin Surg Oncol; 1998; 14(3):232-7. PubMed ID: 9548606 [TBL] [Abstract][Full Text] [Related]
4. An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application. van Der Veen AH; ten Hagen TL; de Wilt JH; van Ijken MG; Eggermont AM Anticancer Res; 2000; 20(5B):3467-74. PubMed ID: 11131649 [TBL] [Abstract][Full Text] [Related]
6. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Nakamoto T; Inagawa H; Takagi K; Soma G Anticancer Res; 2000; 20(6A):4087-96. PubMed ID: 11131677 [TBL] [Abstract][Full Text] [Related]
7. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models. Eggermont AM Gan To Kagaku Ryoho; 1996 Sep; 23(11):1357-70. PubMed ID: 8854755 [No Abstract] [Full Text] [Related]
8. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Rossi CR; Mocellin S; Pilati P; Foletto M; Campana L; Quintieri L; De Salvo GL; Lise M Ann Surg Oncol; 2005 May; 12(5):398-405. PubMed ID: 15915374 [TBL] [Abstract][Full Text] [Related]
9. Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study. Gutman M; Sofer D; Lev-Chelouche D; Merimsky O; Klausner JM Invasion Metastasis; 1997; 17(4):169-75. PubMed ID: 9778589 [TBL] [Abstract][Full Text] [Related]
10. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523 [TBL] [Abstract][Full Text] [Related]
11. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs]. Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515 [TBL] [Abstract][Full Text] [Related]
12. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309 [TBL] [Abstract][Full Text] [Related]
13. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406 [TBL] [Abstract][Full Text] [Related]
14. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. Gérain J; Liénard D; Pampallona S; Baumgartner M; Rüegg C; Buurman WA; Eggermont A; Lejeune F Cytokine; 1997 Dec; 9(12):1034-42. PubMed ID: 9417816 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma. Nachmany I; Subhi A; Meller I; Gutman M; Lahat G; Merimsky O; Klausner JM Eur J Surg Oncol; 2009 Feb; 35(2):209-14. PubMed ID: 18295442 [TBL] [Abstract][Full Text] [Related]
16. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. de Wilt JH; Manusama ER; van Etten B; van Tiel ST; Jorna AS; Seynhaeve AL; ten Hagen TL; Eggermont AM Br J Cancer; 2000 Nov; 83(9):1176-82. PubMed ID: 11027431 [TBL] [Abstract][Full Text] [Related]
17. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805 [TBL] [Abstract][Full Text] [Related]
18. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature. Kayton ML; Libutti SK Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006 [TBL] [Abstract][Full Text] [Related]
19. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan. Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360 [TBL] [Abstract][Full Text] [Related]
20. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]